Masimo - softFlow 50

TNI softFlow® 50

For Spontaneously Breathing Adult Patients in Hospital Environments

  • Respiratory support delivered through a soft nasal cannula interface
  • Wide flow range from 10-60 L/min in 0.5 L/min steps to permit flow rate to be tailored to the specific needs of the patient
  • Ability to supplement oxygen with 0-60 L/min flow from wall supply, oxygen cylinder, or concentrator with FiO2% shown on display
  • Integrated flow driver provides flow without the need for wall air supply
  • Warmed humidification of respiratory gas all the way to the patient’s nose to enhance therapy comfort and aid in mucus clearance1,2 
  • Condensate-free delivery of a consistent, high-velocity flow during inspiration and exhalation to enhance therapy benefits
  • Auto-identification of type of nasal cannula and breathing circuit to improve and simplify workflow through automated configuration 
  • Bacterial/viral filter between device and patient, rather than between device and room air, to reduce risk of cross-contamination

Performance Data

  • Adjustable flow rate: 10-60 L/min ± 2%, adjustable in 0.5 L/min steps to tailor flow to patient needs
  • Supplemental oxygen support: 0-60 L/min, with FiO2% indicator integrated into the display
  • Adjustable humidity/dew point settings from 30-37ºC, adjustable in 1ºC steps to tailor to patient needs
  • Integrated micro-particle filter
  • Nasal applicators include several sizes of soft, flexible nasal prongs to suit a wide range of patients 
  • Disposable bacterial/viral filter (bacterial efficiency >99.999%; viral efficiency >99.99%) between device and patient reduce risk of cross-contamination and transition time between patients 
  • Autofilling humidification water chamber eliminates need to manually refill humidity chamber between uses
  • Entire respiratory circuit is disposable to minimise risk of cross-contamination and reduce time to clean and disinfect the device between patients 

Hospital Model

 
  • Replaceable disposable breathing filter (Bacterial efficiency >99.999%) to reduce risk of cross-contamination between patients
  • Autofilling humidification water chamber – no need to manually check and refill humidity chamber between uses

References:

  1. 1.

    Hasani, A et al. Chron Respir Dis 5, no. 2 (2008): 81-86.

  2. 2.

    Roca, O et al. Respir Care 55, no. 4 (2010): 408-413.

  3. *FDA cleared for use in hospitals and long term facilities. Available for home care use in the US under COVID-19 provisions.

RESOURCES

 

Masimo - Product Information - TNI softFlow 50

Product Information

Use of High-Flow Nasal Therapy on Patients with Suspected or Confirmed COVID-19 COVID-19 is a highly contagious disease, and virtually all forms of respiratory support, including high-flow nasal therapy, pose some risk of disease transmission. The U.S. Food and Drug Administration has stated that ventilating patients with communicable diseases using noninvasive devices without a filtered seal from atmosphere may contaminate room air and increase risk of transmission, and that this risk may be exacerbated by high-flow nasal therapy systems. Some clinicians have also suggested that the use of high flow nasal therapy may facilitate the spread of COVID-19 or other communicable diseases through aerosolization of pathogens. If high-flow nasal therapy is used to treat patients with COVID-19 or other communicable diseases, appropriate precautions should be taken, such as placing a mask over the nose and mouth of suspected and infected patients while on high-flow nasal therapy, isolating patients in negative pressure rooms, and providing caregivers with appropriate personal protective equipment specified for aerosol-generating procedures; however, these precautions cannot guarantee that diseases will not be transmitted to caregivers or others.

For professional use. See instructions for use for full prescribing information including indications, contraindications, warnings and precautions.

PLCO-004509/PLM-12264B-1120